Results 31 to 40 of about 436,330 (367)
Janus kinase inhibitors in autoimmune diseases [PDF]
Annals of the Rheumatic Diseases, 2013 Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea +4 more
openaire +2 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
Clinical drug investigation, 2023 Background and Objectives Janus kinase (JAK) inhibitors are emerging as a therapeutic option for alopecia areata. The risk of potential adverse events is currently debated.
Małgorzata Papierzewska +2 more
semanticscholar +1 more source
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
Translational Neurodegeneration, 2023 Amyotrophic lateral sclerosis (ALS) is a poorly treated multifactorial neurodegenerative disease associated with multiple cell types and subcellular organelles.
Peter J. Richardson +8 more
semanticscholar +1 more source
Ruxolitinib found to cause eyelash growth: a case report
Journal of Medical Case Reports, 2017 Background Hypereosinophilic syndrome is a hematologic disorder in which the eosinophils proliferate. Oral Janus kinase inhibitors are known to be effective treating hypereosinophilic syndrome.
Julia Song +4 more
doaj +1 more source
The Emerging World of JAK Inhibitors
Nepal Journal of Dermatology, Venereology & LeprologyThe Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj +3 more sources
Alopecia areata: a multifactorial autoimmune condition [PDF]
, 2019 Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P. +3 more
core +1 more source
Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Clinical and Experimental Rheumatology, 2022 Dermatomyositis (DM) is an idiopathic inflammatory myopathy that commonly manifests with proximal muscle weakness and is associated with extramuscular pathology, including characteristic skin lesions such as Gottron's papules and heliotrope rash, as well
Julie J. Paik +5 more
semanticscholar +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source